Co-deletion of 1p/19q was associated with extended OS and PFS in patients with glioma, according to results of a meta-analysis.
Factors that influence the prognosis of glioma are not fully understood. Although loss of the heterozygosity of 1p/19q has long been known to be a common molecular signature of oligodendroglial neoplasms, prior research had not established whether loss of 1p/19q was associated with survival outcomes in gliomas, according to background information in the study.
In the current study, researchers reviewed data from the PubMed and Embase databases to examine the association between the loss of heterozygosity of 1p/19q and PFS and OS in patients with glioma. The analysis included 28 studies that included a combined 3,408 cases.
They determined patients with co-deletion of 1p/19q was associated with improved PFS (HR=0.63; 95% CI, 0.52–0.76) and OS (HR=0.43; 95% CI, 0.35–0.53) compared with those in the chromosomal intact group.
Results of a subgroup analysis indicated this association was independent of detection methods and the grades/subtypes of gliomas.
The isodeletion of 1p predicted similar favorable outcomes for PFS (HR=0.68; 95% CI, 0.47–0.97) and OS (HR=0.51; 95% CI, 0.35–0.75). However, isodeletion of 19q was only associated with improved PFS (HR=0.70; 95% CI, 0.56–0.87).
“Isodeletion of 1p predicts similar outcomes but to a lesser extent, whereas the effects of isodeletion of 19q remained only marginal,” the researchers wrote.
Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.